Technical analysis of Nuvalent, Inc. (NUVL): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain.
Price Performance
| 1 month | +0.00% |
| 3 months | +0.43% |
| Year-to-date | +23.23% |
| 1 year | +57.63% |
| 3 years | +178.69% |
52-Week Range
| 52-week High | $123.99 |
| 52-week Low | $71.13 |
| Avg Volume (90d) | 1.7M |
Technical Indicators
| SMA 50 | $113.92 |
| SMA 200 | $104.24 |
| Beta | 1.31 |
| 30-day Volatility (annualised) | 95.0% |
| Price vs SMA 50 | +8.8% |
| Price vs SMA 200 | +18.9% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $99.32 | |
| 2025-11 | $109.35 | +10.1% |
| 2025-12 | $100.59 | -8.0% |
| 2026-01 | $102.89 | +2.3% |
| 2026-02 | $101.95 | -0.9% |
| 2026-03 | $102.45 | +0.5% |
| 2026-04 | $100.28 | -2.1% |
| 2026-05 | $110.39 | +10.1% |
| 2026-06 | $123.50 | +11.9% |
| 2026-07 | $123.96 | +0.4% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | $0.05 | $88M |
| 2026-09-15 | | |
| 2026-09-15 | $0.14 | $2.28B |
| 2026-09-15 | | |
Price
| Price | $123.96 |
| Market Cap | $9.1B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 8.30 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 16.14 |